Загрузка...
Efficacy of fingolimod is superior to injectable disease modifying therapies in second-line therapy of relapsing remitting multiple sclerosis
Although fingolimod is registered in Europe for treatment of relapsing-remitting multiple sclerosis (RRMS) if earlier disease modifying therapy (DMT) has failed, no data regarding its efficacy in this patient group are available. This observational cohort study of the NeuroTransData network includes...
Сохранить в:
| Опубликовано в: : | J Neurol |
|---|---|
| Главные авторы: | , , |
| Формат: | Artigo |
| Язык: | Inglês |
| Опубликовано: |
Springer Berlin Heidelberg
2015
|
| Предметы: | |
| Online-ссылка: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4751192/ https://ncbi.nlm.nih.gov/pubmed/26645389 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s00415-015-7970-6 |
| Метки: |
Добавить метку
Нет меток, Требуется 1-ая метка записи!
|